Pharmos is actively seeking partnership opportunities to expedite development and commercialization of our pipeline assets and to share the risks inherent in drug development. We are interested in entering into alliances with corporate partners under a variety of potential forms, including out-licensing and co-development arrangements. Pharmos is also pursuing partnering opportunities in which we may broaden and enhance our product pipeline by in-licensing compounds in development for indications consistent with our therapeutic focus on disorders of the nervous system including the brain-gut axis (gastrointestinal/irritable bowel syndrome), pain/inflammation and autoimmune disorders.
The Company's Dextofisopam Phase 2b trial for IBS-D+A is now fully enrolled and top
line clinical data is expected late August/early September. Upon successful completion
of the Dextofisopam trial, Pharmos intends to seek a pharmaceutical partner and advance
the drug candidate into Phase 3 testing. Enquiries and expressions of interest are invited.
To learn more about partnering opportunities with Pharmos, please contact us at Info@pharmos-us.com.
